News

The second cohort of investigators selected for project funding through the CRISPR Cures for Cancer Initiative were chosen this June and include researchers at UCSF, Gladstone Institutes, and the Innovative Genomics Institute at UC Berkeley.

Immune cells armed with a mutation first identified in cancer cells gain potency but don’t turn cancerous themselves.

A new, precision-targeted delivery method for CRISPR-Cas9 enables gene editing on very specific subsets of cells while still in the body — a step toward a programmable delivery method that would eliminate the need to obliterate patients' bone marrow and immune system before giving them edited blood cells.

More than a decade ago, pioneering biochemist Jennifer Doudna co-invented CRISPR, the gene editing technology which earned her the Nobel Prize in chemistry. Now, the very first treatment based on CRISPR has been approved in the U.K. and the U.S., a landmark decision for the treatment of sickle cell disease and for the potential of this rapidly advancing field.

In a study of historic scale, scientists at Gladstone Institutes have created an intricate map of how the immune system functions, examining the molecular structures governing human T cells using the next-generation CRISPR tool known as base editing.

At the recent American Society of Hematology Annual Meeting and Exposition, experts agreed that with the advent of genome editing, currently available CAR T cells may be the tip of the iceberg in cellular immunotherapy.

On November 9, 2023, investigators from the CRISPR Cures for Cancer network will present their latest work. Learn how they apply cutting-edge technologies to the design and development of novel therapeutic approaches for cancer.

Announcing the launch of CRISPR Cures for Cancer, a tri-institutional initiative between UCSF, Gladstone Institutes, and the Innovative Genomics Institute at UC Berkeley, which aims to accelerate cell therapy design and development using genomic technologies.

The first cohort of investigators selected for project funding through the CRISPR Cures for Cancer Initiative were chosen this past July and include researchers at UCSF, Gladstone Institutes, and the Innovative Genomics Institute at UC Berkeley.

Scientists used a new method to screen 10,000 combinations of gene edits in immune cells engineered to fight cancer.

A new study explains how understudied cells in the immune system, called gamma delta T cells, can target cancer cells for destruction.

With a slew of tools to trick out immune cells, researchers are expanding the repertoire of CAR-T therapies.

Researchers at the Gladstone-UCSF Institute of Genomic Immunology are learning how to harness the power of the human immune system in new ways.

A new approach by UCSF researchers analyzes how well different re-engineered T cells work against cancer.

A team of scientists at Gladstone and UCSF developed a new approach using CRISPR to produce massive quantities of cells for therapeutic applications.

A gene not previously known to regulate immunity could turn tired T cells around.

Kole Roybal and his team developed a comprehensive rule book for the design of therapeutic cells with improved specificity and safety, and for the eventual customization of cell-based therapies.